GlassScriptPhysician profile
Christine Daisey
NPI 1487917910
$3,086.49
in general payments reported to CMS, 2019-2025
23 companies · $961 in 2025
The $961 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $474 · 2023: $385 · 2024: $1,069 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $911.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $398.00 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $261.76 | 2022-2025 | |
| Amgen INC. | $259.37 | 2023-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $225.54 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $213.43 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.76 | 2021-2025 | Jardiance |
| Pfizer INC. | $128.59 | 2023-2025 | |
| Daiichi Sankyo INC. | $91.79 | 2022-2024 | Injectafer |
| Agios Pharmaceuticals, INC. | $88.12 | 2024-2025 | Pyrukynd |
| Exact Sciences Corporation | $70.59 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Optinose US, INC. | $69.16 | 2024 | |
| Abbvie INC. | $49.67 | 2024-2025 | |
| Ibsa Pharma INC. | $31.17 | 2022-2024 | Tirosint, Flector, Licart |
| Currax Pharmaceuticals LLC | $30.07 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.56 | 2024 | Evkeeza |
| Lundbeck LLC | $18.52 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $16.05 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $14.50 | 2023 | Steglatro |
| Alexion Pharmaceuticals, INC. | $13.65 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $13.62 | 2023 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $12.97 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Daisey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.